ABSTRACT
Gabapentin is eliminated in the urine in unchanged form. Its renal clearance is directly related to creatinine clearance. Thus, the usual recommended dosage of gabapentin must be adjusted for patients who have kidney dysfunction in order to prevent the accumulation of gabapentin and possible toxicity. Gabapentin pharmacotherapy is generally indicated for short-term pharmacotherapy. Opening and mixing the contents of gabapentin capsules with food does not significantly impair absorption and may facilitate ingestion. Gabapentin is moderately well absorbed following oral ingestion. Gabapentin pharmacotherapy generally is well tolerated. However, gabapentin pharmacotherapy has been commonly associated with involuntary cyclical movement of the eyeball (nystagmus), dizziness, fatigue, incoordination (ataxia), and somnolence. The signs and symptoms of gabapentin overdosage include diarrhea, double vision (diplopia), drowsiness, lethargy, and slurred speech.
